Samadder NJ, et al. - A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. In this double-blind, placebo-controlled, randomized trial, it was noted that familial adenomatous polyposis (FAP) patients who received combination treatment with sulindac and erlotinib, compared with those treated with placebo, exhibited significantly lower colorectal polyp burden after 6 months of treatment. Furthermore, there was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum.